Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

People are discussing the potential of a new hair loss treatment, pp405, and its approval timeline, comparing it to existing treatments like Minoxidil and finasteride. There is skepticism about its effectiveness and concerns about the time it will take for approval and availability, especially in Europe.

A user is considering switching to a topical treatment containing finasteride, minoxidil, and tretinoin, instead of their current regimen of oral finasteride and oral minoxidil. They are unsure whether to try the new topical or continue with their current treatment.

Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.

The conversation is about hair regrowth progress using hormone replacement therapy (HRT) with Estradiol and Cyproterone, without using Minoxidil. The user shares progress pictures over 0, 3, and 6 months.

The user has been using minoxidil for hair loss and is considering trying a compounded topical treatment with 0.1% dutasteride, minoxidil, tretinoin, collagen, and silicon, as recommended by a trichologist. They learned that dutasteride might be more effective than finasteride and are seeking opinions on the use of topical dutasteride.

The user is using finasteride, minoxidil, and ciclopirox shampoo for hair loss and is considering adding a topical anti-androgen like RU58841, Clacosterone, or KX286. They have scheduled a hair transplant and are concerned about the cost and effectiveness of future treatments.

A user is exploring Kadeso, a product with Capilia Longa™ for hair regrowth, and seeks real-world experiences, comparing it to Minoxidil and Finasteride. They are interested in results, timeframe, side effects, and the credibility of the product's founder.

HopeMed is upset with Absci for allegedly using misleading information about HMI-115's performance compared to ABS-201. HopeMed plans to take legal action to protect its confidential data and trade secrets.

The user has been using oral finasteride and minoxidil since mid-April and sees progress on the crown but not the front, considering a hair transplant. Suggestions include continuing medication, adding microneedling, and possibly getting a hair transplant for areas with no hair.

There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.

The conversation discusses a botanically derived treatment for androgenetic alopecia using ingredients like saw palmetto, green tea, and evening primrose, showing impressive results over 270 days. Concerns include the study's uncontrolled nature and potential product motivation, with suggestions to enhance absorption through derma rolling.

PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.

PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.

The conversation discusses the difference between the commercially available Pyrilutamide and the version in clinical trials. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

A 29-year-old shared their crown hair recovery using a daily liposomal topical solution of finasteride and minoxidil, low-level light therapy, and specific vitamins, noting significant improvement without side effects. They experienced issues with oral finasteride previously but not with the topical treatment.

A 19-year-old is using topical minoxidil 7% and finasteride 0.1% foam, along with a laser cap, to combat hair loss. They report progress despite initial shedding and are considering switching to oral finasteride in the future for convenience.

The user is using topical minoxidil, topical finasteride, tretinoin cream, microneedling, and ketoconazole and caffeine shampoo for hair regrowth. They are satisfied with the progress but unsure if more regrowth is possible and are advised to continue the routine for a year.

The user suspects scarring alopecia and is exploring NSAIDs and turmeric/pepper for inflammation-related hair loss, having experienced burning and thinning with finasteride and testosterone reduction. They are seeking feedback while unable to afford a dermatologist.

The user tried Redensyl but stopped using topical finasteride and continued with 5% minoxidil. They are experiencing hair loss and considering accepting baldness.

The user shared progress pictures and discussed their hair loss treatment routine, which includes minoxidil, finasteride, Nizoral, dermastamping, tretinoin, rosemary oil, hair peptides, biotin, and collagen supplements. They are seeking advice on hair transplantation, minoxidil application, and the impact of testosterone replacement therapy on hair loss.

PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.

Verteporfin is being explored for hair regeneration, with unofficial trials and updates shared online. Efforts are being made to encourage more surgeons to trial verteporfin for donor hair regeneration.

The conversation is about a topical spray containing finasteride, minoxidil, and tretinoin, with users discussing its effectiveness compared to more established brands. One user mentions using a product with 5% minoxidil, 0.15% finasteride, and 0.15% tretinoin.

RU58841 can be absorbed systemically after topical application, but the study did not find immediate hormonal disruption. The study highlights the need for more research on long-term safety and effects of RU58841, as well as the importance of quality control in products from the grey market.

PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.

CB-03-01 is considered too costly and lacks a proper delivery method, making it less viable compared to RU58841, which has shown effectiveness with minimal side effects. Finasteride caused a drop in libido for one user.

People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.

The user does not respond well to minoxidil and is seeking an alternative to Tretinoin to upregulate sulfurtransferase activity for hair loss treatment. No specific alternative treatments were mentioned.

RU58841 is absorbed systemically in humans, contradicting claims it stays local, but no harm is proven. Alternatives like CB-03-01 or KX-826, especially with finasteride, are suggested for safety.